# Qritive

> Qritive is a Singapore-based healthtech company building AI-powered digital pathology software that helps pathologists detect, grade and classify cancer from whole-slide images. Its Pantheon platform digitizes the entire histopathology workflow, and a suite of hardware-agnostic AI modules - covering prostate, colon, breast, gastric, lymph node metastasis and immunohistochemistry - assist pathologists in reaching faster, more consistent diagnoses. The company sells to hospitals, pathology labs and pharmaceutical partners across Asia-Pacific, the US and the Middle East.

- **Founded:** 2017
- **Headquarters:** Singapore, Singapore
- **Founders:** Aneesh Sathe (Co-founder (PhD Mechanobiology, NUS); founding CEO), Kaveh Taghipour (Co-founder & CTO (PhD Natural Language Processing, NUS))
- **Team size:** ~12 employees
- **Products:** Pantheon, QAi Prostate Grade, Colon Cancer AI Module, Lymph Node Metastasis AI, Immunohistochemistry (IHC) / Biomarker Analysis
- **Notable:** Raised $7.5M Series A led by MassMutual Ventures (January 2023)., Pantheon digital pathology platform received a CE Mark., QAi Prostate Grade received Class C IVD approval from Singapore's Health Sciences Authority (August 2025).

## Products & services

- **Pantheon** — AI-powered, vendor-agnostic digital pathology platform that digitizes the full histopathology workflow - case management, whole-slide viewing, synoptic reporting, telepathology, remote access and LIS integration - in a single window. Received a CE Mark.
- **QAi Prostate Grade** — AI diagnosis tool for prostate cancer that identifies and grades malignancy on whole-slide images. Received Class C IVD approval from Singapore's HSA (2025) and regulatory approval from Abu Dhabi's Department of Health.
- **Colon Cancer AI Module** — AI module for detecting and grading colorectal malignancy on digitized slides.
- **Lymph Node Metastasis AI** — AI module that flags metastatic cancer in lymph node sections to support staging.
- **Immunohistochemistry (IHC) / Biomarker Analysis** — AI-driven biomarker quantification shown in a Singapore General Hospital study to reduce diagnostic subjectivity and discordance by 9.4%.

## Achievements

- Raised $7.5M Series A led by MassMutual Ventures (January 2023).
- Pantheon digital pathology platform received a CE Mark.
- QAi Prostate Grade received Class C IVD approval from Singapore's Health Sciences Authority (August 2025).
- QAi Prostate Grade received regulatory approval from Abu Dhabi's Department of Health (2025).
- Partnership integrating Qritive AI into Roche's navify Digital Pathology platform (2024).
- MedTech Innovator Asia Pacific 2024 finalist.
- IHC AI module shown to cut diagnostic subjectivity by 9.4% in a Singapore General Hospital study.

## Latest updates

- **2025-08** — QAi Prostate Grade received Class C IVD registration from Singapore's Health Sciences Authority, clearing it for clinical use in Singapore labs.
- **2025-07** — QAi Prostate Grade received regulatory approval from Abu Dhabi's Department of Health, extending the tool into the Middle East.
- **2024-09** — Qritive announced a partnership integrating its AI into Roche's navify Digital Pathology platform for colon, prostate, breast and gastric cancers.
- **2024-01** — Named a MedTech Innovator Asia Pacific 2024 finalist.
- **2023-01** — Closed a $7.5M Series A led by MassMutual Ventures with SEEDS Capital and Exfinity Venture Partners.

## Links

- Website: https://qritive.com
- LinkedIn: https://www.linkedin.com/company/qritive
- Twitter/X: https://twitter.com/qritive

---

Profile page: https://yespress.io/qritive
Published by YesPress — https://yespress.io
Last updated: 2026-07-25